It is very uncertain whether meropenem changes serious adverse events maximum compared with standard care (very low certainty).
It is very uncertain whether vancomycin plus gentamicin changes serious adverse events maximum compared with vancomycin plus aztreonam (very low certainty).
It is very uncertain whether cefazolin plus amikacin changes serious adverse events maximum compared with vancomycin plus amikacin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes serious adverse events maximum compared with flucloxacillin and gentamicin (very low certainty).
It is very uncertain whether cloxacillin plus amikacin changes serious adverse events maximum compared with cefotaxime plus gentamicin (very low certainty).
It is very uncertain whether piperacillin changes serious adverse events maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether ampicillin plus gentamicin changes serious adverse events maximum compared with penicillin plus gentamicin (very low certainty).
It is very uncertain whether piperacillin plus tazobactam changes serious adverse events maximum compared with amikacin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes serious adverse events maximum compared with piperacillin plus gentamicin (very low certainty).
It is very uncertain whether cefepime changes serious adverse events Maximum compared with ceftazidime (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.